Supernus Pharmaceuticals Acquires Sage Therapeutics to Strengthen Presence in Neuropsychiatric Conditions

Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics, adding a fourth growth product, ZURZUVAE, and diversifying its revenue base. The acquisition is expected to be accretive in 2026 and brings in collaboration revenue from net sales of ZURZUVAE. Supernus also gains a CNS discovery platform and expects cost synergies of up to $200 million annually. The acquisition strengthens its presence in neuropsychiatric conditions and positions it for significant future growth.